iRhythm Technologies Q4 2024 Earnings Report

iRhythm Technologies EPS Results

• Actual EPS: $0.01
• Consensus EPS: -$0.29
• Beat/Miss: Beat by +$0.30
• One Year Ago EPS: N/A

iRhythm Technologies Revenue Results

• Actual Revenue: $164.33 million
• Expected Revenue: $158.30 million
• Beat/Miss: Beat by +$6.04 million
• YoY Revenue Growth: N/A

iRhythm Technologies Announcement Details

• Quarter: Q4 2024
• Date: 2/20/2025
• Time: After Market Closes

iRhythm Technologies (NASDAQ:IRTC), a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.